CZLhaust
Lv1
20 积分
2024-04-20 加入
-
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
8天前
已完结
-
The gut microbiota in obesity and weight management: microbes as friends or foe?
9天前
已完结
-
Management of Monogenic and Syndromic Obesity
10天前
已关闭
-
Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks
10天前
已完结
-
Contemporary medical, device, and surgical therapies for obesity in adults
10天前
已完结
-
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
11天前
已完结
-
Current and future state of pharmacological management of pediatric obesity
11天前
已完结
-
Lac-Phe mediates the effects of metformin on food intake and body weight
12天前
已完结
-
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
12天前
已完结
-
Child and adolescent obesity
12天前
已完结